India-based Veeda Group on Thursday unveiled a new logo and brand identity, Veeda Lifesciences.
The company said that the new brand name reflects its evolution from a generics-focused Contract Research Organisation (CRO) to a drug development services enterprise for different modalities of drugs including generics and novel chemical and biological entities. Veeda Lifesciences will operate through four Strategic Business Units: Clinical Trials, Healthy Volunteer Services, Biopharma Services, and Preclinical & Non-Clinical Testing Services, making Veeda an integrated research service provider.
Veeda Lifesciences integrates Veeda Clinical Research, Health Data Specialists, and Bioneeds India, showcasing research services across various stages of the drug development value chain from discovery and preclinical to late-phase development. The new identity reflects the company's transition from generics to innovation, local to global, and small molecules to biologics. Veeda Lifesciences is transitioning to a CRO-CDMO model, while leveraging AI and real-world data.
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets
Newbury Pharmaceuticals secures approval for Macitentan in Denmark
Mallinckrodt and Endo to merge in USD6.7bn deal to create pharmaceutical leader
Genomma Lab Internacional announces quarterly dividend
Aveva Drug Delivery systems introduces generic Fentanyl Transdermal Patch in US
Independent Pharmacy Cooperative signs cooperation agreement with Legacy Pharmacy Group
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Newbury Pharmaceuticals secures generic approval for pomalidomide in Denmark
Newbury Pharmaceuticals secures generic approval for Bosutinib in Norway
Guangzhou Fermion Technology partners with Simcere Pharmaceutical